Regeneron tops quarterly estimates, plans to resubmit Eylea application
Update: 2025-10-29
Description
Regeneron Pharmaceuticals exceeded Wall Street expectations in Q3, driven by robust sales of Dupixent and Libtayo. Dupixent's sales surged by 27%, while Libtayo outperformed estimates. Regeneron's revenue and profit per share also beat expectations, causing a 10% stock price increase. Despite challenges with Eylea's approval, Regeneron plans to resubmit its application by January 2026, aiming for mid-year approval. The company is also exploring strategic deals to maintain growth post-Dupixent exclusivity.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
